|
|
|
|
|
|
|
|
|
|
SAN DIEGO, March 21, 2011 /PRNewswire/ -- Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer. The publication is now available on the International Journal of Gynecological Cancer website and scheduled to print in the May issue of the journal......
abstract: Int J Gynecol Cancer. 2011 Mar 15. [Epub ahead of print]
Blogger's Note: at the time of the initial Phenoxodiol clinical trials I advocated, without success, bringing this trial to Canada. Why? Because initial results/suppositions indicated a lack of treatment-related adverse events (QOL). The efficacy obviously was to be shown as per these most recent results (overall 19/20% which includes stable disease - more details req'd). Accrual in the initial Phenoxodiol trials was an issue, so possibly, with more research data/advances in molecular biology the accrual process will become less onerous. In the past decade the only progress since the Taxol/Carbo era has been Avastin and while PFS is noted, toxicity issues remain a concern albeit to date a small risk. Having said this, I have known women personally who have died on the initial Avastin/combo trials which makes this an 'it's only rare if it's not you' personal observation.
ReplyDelete